International Top Pharmaceutical Awards

Description: The AI revolution is transforming clinical research by accelerating drug development , enhancing patient recruitment, and enabling precise data analysis. With advanced algorithms, AI is redefining the way researchers approach challenges, ensuring faster, more accurate outcomes that pave the way for groundbreaking treatments. International Top Pharmaceutical Awards Website link : toppharmaceutical.org Nomination : toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee Contact us: contact@toppharmaceutical.org #sciencefather #researchawards #clinicalresearch #artificialintelligence #aitechnology #medicalinnovation #aiinmedicine #drugdevelopment #precisionmedicine #healthtech #clinicaltrials #medicaladvancement #aihealthcare #patientcare #healthinformatics #digitalhealth #aiforhealth #medtechinnovation #aialgorithms #aiapplications #researchinnovation #dataanalytics #aiimpact #aiinscience #pharmatech #medtech #advancedhealthcare #pharmainnovation, #dru...

The strategy involves delivering genetic information for two types of molecules: a light-sensitive protein known as CoChR that can produce positively charged currents, and a bioluminescence-emitting enzyme. Packed into an altered virus particle and delivered to cancer cells, the proteins are produced as their genes are expressed in mitochondria. A follow-up injection of a specific chemical turns on the enzyme’s light to activate CoChR, which leads to mitochondrial collapse. The other half of the battle is ensuring this therapy does not interfere with normal cells. Liu’s lab specializes in targeted anti-cancer therapy development. The foundation for the delivery system in this work is the well-characterized adeno-associated virus (AAV), a minimally infectious virus engineered to carry genes and promote their expression for therapeutic purposes. The team refined the system to enhance its cancer specificity by adding a promoter protein to drive up expression of the CoChR and biolumine...

New safety information for healthcare professionals Veoza (fezolinetant): new recommendations to minimise risk of liver injury The PRAC has agreed to a direct healthcare professional communication (DHPC) informing of the risk of drug-induced liver injury (DILI) with Veoza (fezolinetant) and has recommended monitoring of liver function before and during treatment. Veoza is a medicine used to treat moderate-to-severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with menopause. The committee considered a review of the potential risk of fezolinetant to cause drug-induced liver injury based on information from all available sources, including reports of suspected side effectsand studies published in the scientific literature. Severe elevations of the liver enzymes alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (>10x upper limit of normal) with concurrent elevations in bilirubin and/or alkaline phosphatase (ALP) have been reporte...

This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...

Offering hope to around 136,000 Haemophilia A patients in India, the Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore, announced that they have successfully executed a first-in-human gene therapy using lentiviral vectors for the disease. Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia. Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, intravenous (IV) access in children, and low patient acceptance.The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results, according to scientists involved in the research. “The therapy successfully produced zero annualised bleeding rates in all five enrolled participan...

AMD has appointed Tim Keating as senior vice president of Government Relations and Regulatory Affairs, effective immediately. His experience is expected to enhance the company’s engagement with key stakeholders as the importance of AI and high-performance chips continues to grow. Ava Hahn, AMD’s senior vice president and general counsel, emphasized Keating’s extensive public policy expertise and understanding of regulatory landscapes will be crucial for the company’s future. Keating brings decades of experience, including a significant tenure at Boeing and roles within the U.S. government. Prior to joining AMD, Keating was the executive vice president at Boeing, and he has also held prominent positions at Honeywell and within the U.S. House of Representatives. He holds a bachelor’s degree in political science from the University of Scranton and an honorary doctorate from the University of South Carolina.